Status:
COMPLETED
Thromboelastography to Assess Hemostatic Changes in Patients Undergoing Elective Cesarean Delivery.
Lead Sponsor:
Stanford University
Conditions:
Hemorrhage
Eligibility:
FEMALE
Brief Summary
The purpose of the study is to assess the coagulation changes that occur in patients undergoing elective Cesarean delivery using thromboelastography (TEG). We will compare coagulation data to assess p...
Detailed Description
The purpose of the study is to assess the coagulation changes that occur in patients undergoing elective Cesarean delivery using thromboelastography (TEG). TEG is a point-of-care device which measures...
Eligibility Criteria
Inclusion
- All obstetric patients with singleton pregnancies admitted to the labor and delivery unit at Lucile Packard Hospital who undergo elective Cesarean delivery.
- We will select 100 healthy ASA 1 patients with singleton pregnancies who are scheduled for uncomplicated elective Cesarean delivery, with no anticipated risk of obstetric hemorrhage.
Exclusion
- Patients with underlying coagulation disorders.
- Patients with thrombocytopenia.
- Patients with pregnancy-induced hypertension, pre-eclampsia.
- Patients requiring the following medications prior to surgery: NSAIDS, aspirin, anticoagulants.
- Patients requiring non-elective Cesarean delivery.
- Patients with significant obstetric or medical disease.
- No patients \<18 years of age will be recruited.
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2009
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00767832
Start Date
August 1 2008
End Date
June 1 2009
Last Update
November 9 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305